Merck & Co. vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Global pharma anchored by Keytruda ($25B cancer drug); $63.6B FY2024 revenue; Gardasil China collapse 2024 ($2B loss); Winrevair PAH approval 2024; Keytruda patent cliff 2028-2030 is defining challenge.
About
Merck & Co. is one of the world's largest research-driven pharmaceutical companies, founded in the United States in 1891 as a subsidiary of the German Merck KGaA and now an independent American company headquartered in Rahway, New Jersey, trading on NYSE (MRK). The company generated approximately $63.6 billion in revenues for FY2024 under CEO Robert Davis, anchored by Keytruda (pembrolizumab)—the world's best-selling cancer drug—which generated approximately $25 billion in global sales as the dominant checkpoint inhibitor immunotherapy across over 40 approved tumor indications including lung cancer, melanoma, bladder cancer, cervical cancer, and dozens more. Merck's animal health subsidiary, Merck Animal Health, is a global leader in livestock and companion animal medicines including Bravecto (flea/tick prevention) and contributes approximately $6 billion in revenues.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.